Drug Type Oncolytic virus |
Synonyms MV NIS, MVNIS, Sodium Iodide Simporter Measles Virus + [2] |
Target |
Mechanism NIS modulators(solute carrier family 5 member 5 modulators), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 2 | US | 18 Mar 2015 | |
Fallopian Tube Carcinoma | Phase 2 | - | Vyriad, Inc.Startup | - |
Ovarian Cancer | Phase 2 | - | Vyriad, Inc.Startup | - |
Peritoneal Neoplasms | Phase 2 | - | Vyriad, Inc.Startup | - |
Squamous Cell Carcinoma | Phase 1 | US | - | 19 May 2019 |
Breast Cancer | Phase 1 | US | - | 20 Apr 2019 |
metastatic non-small cell lung cancer | Phase 1 | US | Vyriad, Inc.Startup | 03 Aug 2017 |
Recurrent Non-Small Cell Lung Cancer | Phase 1 | US | Vyriad, Inc.Startup | 03 Aug 2017 |
Glioblastoma | Phase 1 | US | Vyriad, Inc.Startup | - |
Head and Neck Neoplasms | Phase 1 | US | Vyriad, Inc.Startup | - |
Phase 1 | 2 | syntymwrcd(rvbxcmakwm) = npgriljpqf fegrnvfsep (issiorqqhc, qhvscqqowl - hehdqvcjhy) View more | - | 21 Jul 2023 | |||
Phase 1 | Transitional Cell Carcinoma Neoadjuvant | 8 | xzrmnvvaaw(krkoekokhz) = Only a single Adverse Event (AE) attributable to MV-NIS treatment (Grade 1 hematuria) rhqmkgicko (thidjfrdtc ) | Positive | 16 Feb 2022 | ||
Phase 2 | 2 | shakpyeepx(hdkqsssmmw) = qhacypczrn bbydukhptk (ofbcxevbka, tupnvmusjz - ajnuwkqrgj) View more | - | 19 Oct 2020 | |||
Not Applicable | Malignant Pleural Mesothelioma Second line | 12 | gufeqmaplz(ksuishoqoe) = plbupfkisp yexyargfmz (gbnszcyofk, 221, 484) | - | 06 Dec 2016 |